Insights

In this whitepaper we examine the potential rewards of sustainable yet multidimensional business growth and reveal why whole system mapping is a prerequisite for driving essential system-level – not just product-level – innovation.

The changing regulatory and subsidy systems underpinning farming are undergoing radical change. Furthermore, issues such as soil health, net zero and farm nature value are increasingly in the public eye.

Real-time nitrate sensing holds the potential for significant yield increases, cost savings, and environmental impact reduction. 

The number of effective cell and gene therapies is growing rapidly, especially for treating ocular diseases. However, much less attention has been focused on the critical issue of delivery to the eye. 

If you’re a surgical robotics start-up, the timing of your risk assessment will determine the level of success you achieve. Andrew Savarese, VP, Surgical Robotics & Advanced Surgical Systems, delves into his deep experience and comes up with crucial advice to make sure you spend the right money once, not the wrong money twice.

Intraocular lens (IOL) delivery devices are the next frontier for innovation and differentiation. As the optical quality of the IOL is reaching its apex, there's little room for competitive differentiation in the lens itself. Tim Phillips explores the improvements to IOL delivery devices that could reduce complications, streamline delivery workflow and improve postoperative patient satisfaction.

Intravitreal Injection Syringe: It is merely a pre-filled syringe, but is it?

Now you’ve got a talented team together, surely it’s time to push on to design and build your device? Not quite. In the latest in his series of articles, our VP Surgical Robotics & Advanced Surgical Systems Andrew Savarese explains the crucial importance of system architecture, the vital blueprint for project efficiency… 

The ophthalmology world is welcoming a new wave of sophisticated implant technology designed to transform diagnosis and treatment.

Sustainability emerged as a hot and emotive topic at this year’s Drug Delivery to the Lungs (DDL) conference, read Donal Taylor's thoughts on other key trends that emerged.

Only two companies at the top of the Fortune 500 have survived from 20 years ago. The newcomers have risen by being fleet of foot or riding a financial or technological wave.

Matt Garwood challenges the medical device development status quo. If we embrace a bold, comprehensive response that begins at the concept stage and ends with the device user, it is possible to challenge conventional thinking and change for the better.